Retrophin (RTRX) Misses Q3 EPS by 23c, Revenues Miss

Retrophin (NASDAQ: RTRX) reported Q3 EPS of ($0.68), $0.23 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $40.71 million versus the consensus estimate of $44.36 million.

“I am pleased with the continued advancement of our first-in-class fosmetpantotenate and sparsentan programs and look forward to generating our first pivotal top-line data readout from the FORT Study next year. Additionally, the Phase 2 proof-of-concept study of CNSA-001 in PKU is underway and we are looking forward to seeing the results from that study in the first half of 2019,” said Stephen Aselage, chief executive officer of Retrophin. “The third quarter also continued our four-year history of delivering period over period revenue growth; while revenue came in below our internal expectations for the quarter, we expect to continue the period over period revenue growth trend in the fourth quarter. Overall, the progress made in the third quarter sets us up to meet additional strategic milestones and end 2018 well-positioned for the coming year.”

For earnings history and earnings-related data on Retrophin (RTRX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c